Estee Lauder Companies Inc (EL): what the price requires

At today's price, Estee Lauder Companies Inc (EL) is priced for today's economics sustained for ~7.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Source: https://boothcheck.com/report/EL

Headline

FieldValue
TickerEL
CompanyEstee Lauder Companies Inc
Current price$81.16/sh
CompositionSkin Care 49% / Makeup 29% / Fragrance 17% / Hair Care 4% / Other 1%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed12.3%
Operating margin today7.5%
Margin expansion implied+4.8pp
Must persist for7.5y
Multiple paid33x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: high

ReferenceValue
vs own history+0.56σ
cohort percentile (of 69 peers)80
sustained it ~7.5 years at this level29%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power/growth-DCF land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset7.84x2expensive
Earnings7.38x3expensive
Relative1.00x3justifies
Growth1.53x3expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.2%); the inversion above states its own rate.

Per-Model Detail (n=11)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$28.032.90xyesFCF base $1.3B, growth 0% (input: historical growth), terminal g 0.5%, WACC 7.2%, 5yr projection
DCF Exit MultipleGrowth$70.711.15xyesExit EV/EBITDA: 29.1x / 31.1x / 33.1x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$81.191.00xyesP/S fallback (negative EPS): Sector P/S 2.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$10.937.43xyesReference only (book value floor): BV/sh $10.93, ROE negative
Two-Stage Excess ReturnAsset$9.838.26xyesReference only (book value with convergence): BV/sh $10.93, ROE converges to ke
Discounted Future Market CapGrowth$53.061.53xyesRev $14.8B, growth 0% (input: historical growth; tapered), Terminal P/S: 1.7x / 2.0x / 2.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$10.997.38xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.55B × (1−40%) / WACC 7.2% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$23.323.48xyesEBITDA $1.24B × sector EV/EBITDA 14.0x
FCF YieldEarnings$13.945.82xyesFCF $1285.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$4.9816.30xyesSBC-adj FCF $0.98B (FCF $1.28B − SBC $0.30B) capitalized at Kₑ
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$1.7646.11xyesBV $10.93 × (ROIC 1.2% / WACC 7.2%) (excluded from median)
P/Sales SectorRelative$81.191.00xyesRevenue $14.83B × sector P/S 2.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$7.3b
Net debt / NOPAT (after-tax)13.08x
Net debt / operating income (pre-tax)6.50x
Interest coverage3.3x
Share count CAGR (dilution)0.1%
Burning cashno

Bullet Takeaways

Estée Lauder is a trough-earnings turnaround: trailing operating margin of just 2.9% reflects the China and travel-retail collapse plus restructuring, but the prestige-beauty franchise still earns a 76.4% gross margin, and the Profit Recovery and Growth Plan lifted adjusted operating margin 360 basis points to 15.0% in the third quarter of fiscal 2026.

The price embeds the recovery, not the trough: it implies a normalized operating margin near 13%, which matches management's preliminary fiscal 2027 guide of 12.5% to 13.0%, and the company raised full-year fiscal 2026 adjusted EPS guidance to $2.35 to $2.45 with fragrance organic sales up 10% and China growing for a third straight quarter.

The models disagree sharply and the conservative ones price the risk: earnings-power and book-value frames mark $10 to $14 on the depressed earnings while relative frames near $73 to $81 assume recovery; with the multiple at the top of the peer distribution, interest coverage near 1.3x, a cut dividend, and a workforce reduction of nearly 17.5%, the downside is real if the turnaround stalls.

Bull Case

Valuing prestige beauty requires holding two facts at once: the brand portfolio is a durable, high-margin asset, and the current earnings are a cyclical trough, not the run-rate. Estée Lauder's reported operating margin sat near 2.9% on a trailing basis, a number that would be alarming for almost any other company, but it reflects the China travel-retail collapse and the cost of a sweeping restructuring rather than a broken business. The signature of a prestige-beauty franchise is a 76%+ gross margin, and Estée Lauder still earns it: in the third quarter of fiscal 2026 gross margin expanded 140 basis points to 76.4%. A business that keeps that gross margin through a demand shock has not lost its pricing power; it has lost a cycle.

The turnaround is producing real margin recovery, which is the metric that matters for this name. The Profit Recovery and Growth Plan drove adjusted operating margin up 360 basis points to 15.0% in the quarter, more than offsetting roughly $100 million of tariff headwinds, and management expanded the restructuring to cut 9,000 to 10,000 jobs for up to $1.2 billion in gross benefits. The demand side is turning too: fragrance organic sales rose 10%, led by luxury labels Le Labo, KILIAN PARIS, and TOM FORD, and Mainland China posted mid-single-digit organic growth for a third consecutive quarter of outperforming prestige beauty. The 10-K describes the breadth of the portfolio across skin care, makeup, fragrance, and hair care and the role of new product innovation in purchasing decisions (FY2025 10-K, accession 0001001250-25-000099).

The forward path is what justifies looking past the trough. Estée Lauder raised full-year fiscal 2026 adjusted EPS guidance to $2.35 to $2.45 and gave a preliminary fiscal 2027 view of 3% to 5% net sales growth with adjusted operating margin of 12.5% to 13.0%, a roughly 500-basis-point improvement from the start of the recovery plan. That implied normalized margin near 13% is precisely what the price embeds, so the bet is that the recovery the company is already demonstrating continues. For a portfolio of irreplaceable prestige brands recovering margin off a clear trough, the value case is that normalized earnings power, not the depressed trailing figure, is what the stock is worth.

Bear Case

The models disagree violently on Estée Lauder, and the conservative ones are the more honest read of a company still in the early innings of an unproven turnaround. The frames that value the business on its current, depressed earnings mark it far below the price: the earnings-power value model near $11, the free-cash-flow capitalization near $14, and the book-value floor near $10 to $11 (reference only, since trailing return on equity is negative). Against an $84.80 price (June 27, 2026), those are not close. The optimistic case requires believing the margin recovers to roughly 13% and holds, and the price already assumes it. If the recovery stalls, the stock is anchored to the trough frames, not the recovery ones, and the downside is severe.

The operational reality behind the trough is not fully resolved. The collapse was driven by the China and travel-retail business, and the 10-K describes elevated inventory levels and destocking at certain retailers in the second half of fiscal 2025 (FY2025 10-K, accession 0001001250-25-000099). Travel retail and Chinese prestige demand remain volatile, and management itself flagged a roughly 2-percentage-point headwind to fourth-quarter sales from business disruptions in the Middle East. A turnaround that depends on the most volatile geographies and channels recovering on schedule is exposed to exactly the regions that caused the problem. The restructuring, now cutting nearly 17.5% of the workforce, is necessary but disruptive, and deep cuts can damage the brand-building and innovation capability that the business runs on.

The valuation and balance sheet leave no cushion for a setback. At about 34x company-wide operating income, the inversion reads the price as requiring growth held near a self-funding ceiling for roughly eight years, a multiple the engine flags as sitting at the very top of the peer distribution, well beyond the upper quartile, and only about 26% of comparable fast-growers have sustained that kind of run. Net debt is high relative to the depressed operating income (interest coverage of only about 1.3x on trailing numbers), so the leverage is uncomfortable until the margin recovers. The company also cut its dividend to preserve flexibility, a signal that the recovery is consuming cash. The bear conclusion is that Estée Lauder is a great brand portfolio priced for a full margin recovery that has begun but is far from secured, and the conservative models, not the optimistic ones, are pricing the risk that it falls short.

Valuation

Estée Lauder is a trough-earnings story, and the models scatter because they disagree on whether to value the trough or the recovery. The frames that capitalize current depressed earnings mark far below the price: earnings power value near $11, free-cash-flow yield near $14, and the book-value floor near $10 to $11 (reference only, given a negative trailing return on equity). The frames that look forward or use multiples land closer: the relative price-to-sales frame near $81, the exit-multiple DCF near $73, and the discounted-future-market-cap frame near $55. The price is justified by the relative-multiple frame while the asset, earnings-power, and growth-DCF frames say expensive, which is the expected pattern for a company whose earnings are temporarily collapsed but whose revenue base is intact.

The key to the valuation is the implied margin. The inversion reads the price as embedding a normalized operating margin near 13%, well above the trailing 2.9%, which means the market is explicitly pricing a margin recovery, not the current trough. That implied 13% matches management's preliminary fiscal 2027 guidance of 12.5% to 13.0% adjusted operating margin almost exactly, so the priced-in assumption is coherent with the company's own plan. The question is execution, not plausibility of the target.

Inverting the price further, the market pays about 34x company-wide operating income, which the engine reads as requiring growth held near its self-funding ceiling for roughly eight years, an elevated read that sits at the very top of the peer distribution. That band should be read as the trough-anchored floor, not a target; the real fair value depends entirely on whether the margin recovers to the guided 13%. The honest read: at $84.80 the stock prices in a successful turnaround that is underway but unproven, with the conservative models marking the downside if the recovery stalls and the relative frames supporting the price only if it completes.

Catalysts

The most recent print was the third-quarter fiscal 2026 report, and it beat and raised. The Profit Recovery and Growth Plan drove gross margin up 140 basis points to 76.4% and adjusted operating margin up 360 basis points to 15.0%, more than offsetting roughly $100 million of tariff headwinds. Fragrance organic sales rose 10%, led by Le Labo, KILIAN PARIS, and TOM FORD, and Mainland China posted mid-single-digit organic growth for a third consecutive quarter. The company raised full-year fiscal 2026 adjusted EPS guidance to $2.35 to $2.45 and the stock rose on the result.

The restructuring is the central ongoing catalyst. Estée Lauder expanded its job-cut target to 9,000 to 10,000 (nearly 17.5% of the workforce) for up to $1.2 billion in gross benefits, with completion expected by the end of 2026. Each quarter's margin progress against the plan, and confirmation that savings land at the high end of the targeted range, are the events that validate or undercut the recovery thesis. New CEO Stéphane de La Faverie is executing the turnaround, and his credibility with investors rides on it.

The forward thesis tracks margin recovery, China and travel retail, and execution. The supportive drivers are the gross-margin resilience, the restructuring savings, the fragrance strength, and the stabilizing China demand. The risks are the volatility of travel retail and Chinese prestige (the source of the original collapse), a flagged 2-percentage-point Middle East headwind to fourth-quarter sales, and the leverage that is uncomfortable until margins recover. Watch the adjusted operating margin against the fiscal 2027 guide of 12.5% to 13.0%, organic sales by region and category, the cadence of restructuring savings, and travel-retail and China trends, since the entire gap between the trough valuation frames and the recovery frames closes or persists on whether the margin returns as planned.

Sources: Estée Lauder Q3 fiscal 2026 results and 8-K (sec.gov, 247wallst.com); Q3 2026 earnings call (Yahoo Finance, Investing.com, TradingView); restructuring expansion and turnaround (Cosmetics Business, Retail Dive, TheStreet); dividend cut and new CEO (Business of Fashion).

Peer Cohorts (Per Segment, With Filing Citations)

Skin Care (reported)

Makeup (reported)

Fragrance (reported)

Hair Care (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive EL report on boothcheck